Tempest (TEM) Q4 2025: Data Licensing Jumps 69% as AI-Driven Platform Pulls Ahead

2026-02-24 | By EarningsIQ Research

Tempest’s integrated AI and diagnostics business delivered accelerating growth, with data licensing revenue surging 69% and core oncology diagnostics up 29% in Q4. The company’s unique combination of proprietary multimodal data and direct clinical distribution is fueling both segment expansion and deepening client engagement, positioning Tempest for sustained outperformance as AI adoption in healthcare intensifies. Management’s guidance and contract visibility reinforce a high-confidence outlook for 2026, with platform effects and technology advantages compounding across business lines.

Summary

• Data Licensing Momentum: Proprietary multimodal datasets and distribution drive rapid expansion of the data business.
• Diagnostics Platform Advantage: Oncology and hereditary test volumes accelerate, supported by differentiated technology and clinical integration.
• Visibility Into 2026: Bookings strength and high net revenue retention set up robust growth and margin expansion for the coming year.

Performance Analysis

Tempest delivered outsized growth across both its diagnostics and data businesses in Q4, with the data segment posting a 69% increase in revenue (including the AstraZeneca warrant impact) and oncology diagnostics units up 29%. Hereditary test volumes also grew 23%, demonstrating resilience despite moderating share gains. The company’s core business, when including the Ambry acquisition, saw revenue climb more than 33% for the year, well ahead of long-term targets.

Data business momentum was underscored by total contract value (TCV) exceeding $1.1 billion and net revenue retention at 126%, reflecting expanding client usage and multi-year commitments. The diagnostics segment’s growth was broad-based, with minimal reliance on any single test or channel, and MRD (minimal residual disease) volumes up 56% quarter over quarter, albeit with only a small portion of the sales force currently enabled to sell the product. Average selling prices (ASP) for tests rose sequentially, and management outlined a path to further ASP gains from product mix and regulatory approvals.

• Data Licensing Acceleration: Strong demand from pharma and biopharma clients, with bookings growth outpacing revenue and driving multi-year visibility.
• Diagnostics Unit Growth: Oncology and hereditary volumes both posted double-digit increases, with liquid biopsy outpacing solid tumor testing.
• Contractual Visibility: Large TCV base and high net revenue retention point to sustained expansion and reduced revenue cyclicality.

Tempest’s dual-engine model—combining diagnostics scale with proprietary data assets—continues to deliver operating leverage and strategic differentiation, reinforcing its position as a leading AI-enabled healthcare platform.

Executive Commentary

Strategic Positioning

1. Proprietary Data and Distribution Moat

Tempest’s core advantage lies in its integrated, proprietary multimodal data—spanning molecular, imaging, and clinical sources—collected through its diagnostics business and directly linked to patient outcomes. The company’s ability to harmonize, structure, and deliver these insights at the point of care through connections to over 5,500 hospitals and thousands of physicians creates a high barrier to entry for potential competitors. This direct clinical distribution, coupled with real-time data generation, underpins the rapid growth and high retention in the data licensing segment.

2. AI-Driven Product Innovation

AI and foundation model investments are compounding the company’s technology lead, with the first oncology foundation model cluster delivered to AstraZeneca and a second, larger cluster deployed for broader applications. These efforts are accelerating the development of new diagnostic modules (such as PagePredict and immune profile scores) that enhance test value and clinical adoption. Management expects these insights to increasingly differentiate Tempest’s offerings and drive further growth in both diagnostics and data.

3. Platform Leverage Across Diagnostics Portfolio

The company’s contextualized diagnostics platform—integrating DNA, RNA, liquid biopsy, and hereditary testing—enables Tempest to offer a comprehensive solution for oncology providers, mirroring the one-stop-shop model seen in other industries. This breadth supports cross-selling, higher ASPs, and deeper integration with clinical workflows, and is increasingly valued by providers seeking to manage risk and patient care across the continuum.

4. Multi-Year Revenue Visibility and Margin Expansion

With more than $1.1 billion in TCV and a significant portion of 2026 revenue already committed, Tempest enters the year with unparalleled bookings visibility. ASP expansion, driven primarily by migration to FDA-approved tests and commercial payer progress, is expected to drive margin gains, with management balancing panel breadth and gross profit optimization across diagnostics and data businesses.

5. Disciplined Capital Allocation and Strategic Focus

Tempest has avoided major sales force reorganizations, instead focusing investment on technology, AI, and expanding its platform capabilities. The Ambry acquisition has broadened the hereditary offering and data capture, supporting the company’s vision of being the comprehensive partner for oncology providers and pharma clients alike.

Key Considerations

Tempest’s Q4 and full-year results reflect a business model firing on multiple cylinders, with AI, proprietary data, and clinical integration driving both growth and defensibility. The following strategic factors frame the quarter’s context and forward trajectory:

Key Considerations:

• AI-Enabled Data Flywheel: Proprietary multimodal datasets are fueling both diagnostic and data licensing growth, compounding competitive advantage as more clinical data is ingested and leveraged for new applications.
• Diagnostics ASP and Product Mix: Migration to FDA-approved XT-CDX and new liquid biopsy offerings (XF) are set to lift ASPs and margins, with commercial payer progress adding incremental upside.
• Sales Force Leverage and MRD Ramp: MRD volumes are growing rapidly with only a fraction of the sales force enabled; full commercialization could unlock significant incremental revenue as reimbursement coverage expands.
• Bookings and Retention Strength: High TCV and 126% net revenue retention signal durable demand and reduced revenue volatility, providing a robust foundation for 2026 guidance.
• Operational Discipline: Management is maintaining focus on technology and platform scale, avoiding distractions from non-core segments and one-off cost optimizations.

Risks

Key risks include reimbursement timing for new diagnostic assays (especially MRD), potential ASP compression if payer dynamics shift, and the challenge of sustaining high growth rates at increasing scale. Competitive pressure from traditional AI and diagnostics players moving into healthcare remains a watchpoint, though Tempest’s proprietary data moat and distribution model offer meaningful insulation. Macro headwinds or regulatory delays could impact revenue recognition and margin expansion.

Forward Outlook

For Q1 2026, Tempest guided to:

• Data business growth of approximately 40% YoY
• Continued acceleration in core diagnostics volume, with oncology and liquid biopsy leading

For full-year 2026, management maintained guidance of:

• $1.59 billion in total revenue
• Approximately $65 million in positive adjusted EBITDA

Management highlighted several factors that reinforce confidence in the outlook:

• Strong bookings and high contract coverage for 2026 revenue
• Ongoing ASP expansion and product mix improvements

Takeaways

Tempest’s Q4 results and commentary reinforce its position as a leading AI-powered diagnostics and data platform, with accelerating growth, expanding margins, and deepening competitive moats.

• Data Licensing Outperformance: Surging demand and high retention are compounding long-term value, with bookings strength translating to multi-year visibility and platform leverage.
• Diagnostics Platform Scaling: Oncology and hereditary test growth is broad-based, with technology-driven differentiation and rising ASPs supporting margin expansion.
• Watch for MRD and AI-Driven Modules: Full commercialization of MRD and continued AI module rollout could unlock significant incremental upside in both diagnostics and data segments.

Conclusion

Tempest’s integrated AI and diagnostics platform is scaling rapidly, with proprietary data and clinical distribution driving accelerating growth and defensibility. The company enters 2026 with high revenue visibility, strong bookings, and expanding margins, positioning it as a leader in the evolving healthcare AI landscape.

Industry Read-Through

Tempest’s results signal a clear shift in the healthcare AI and diagnostics landscape: proprietary multimodal data assets, integrated with clinical workflows, are now critical for both defensibility and growth. Competitors lacking direct data access and clinical distribution will face mounting barriers to entry, while those with platform breadth and AI-enabled insights can capture expanding share in diagnostics and data licensing. Pharma and provider demand for actionable, real-world datasets is accelerating, with retention and contract value emerging as key metrics for sector leaders. Expect increased M&A and partnership activity as traditional players seek to replicate Tempest’s integrated model, and watch for continued ASP and margin expansion as FDA approvals and payer coverage progress across the industry.

TEM Healthcare Diagnostics Artificial Intelligence Data Licensing Oncology Platform